---
document_datetime: 2023-09-21 17:57:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/temodal-epar-procedural-steps-taken-authorisation_en.pdf
document_name: temodal-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3801796
conversion_datetime: 2025-12-19 11:34:49.751879
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant SP Europe submitted on 8 January 1998 an application for Marketing Authorisation to the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for  Temodal,  through  the centralised  procedure.  After  agreement  by  the  CPMP  in  November  1996,  this  medicinal  product  is referred to Part B of the Annex to Council Regulation No (EC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP  were:

Rapporteur:

A. Hildebrandt

## Licensing status

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 30 January 1998.
- The  Co-Rapporteur's  first  assessment report was  circulated  to  all  CPMP  members  on 10 April 1998. The Rapporteur's first assessment report was circulated to all CPMP members on 16 April 1998.
- During the meeting on 26-27 May the CPMP agreed on the consolidated list of questions to be sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the  company  on 28 May 1998.
- The company submitted the responses to the consolidated list of questions on 10 July 1998.
- The Rapporteur circulated the joint response assessment report on the company's responses to the list of questions to all CPMP Members on 1 September 1998.
- The CPMP, during its September 1998 plenary meeting, adopted a list of outstanding issues to be addressed by the by the applicant in an oral explanation at the October CPMP meeting.
- A  joint  Rapporteur's  and  Co-Rapporteur's  statement  on  the  benefit/risk  assessment  was circulated to all CPMP members on 17 September 1998.
- Oral explanations were given by the applicant on 20 October 1998.
- During the meeting on 20-22 October 1998 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation for Temodal on 22 October 1998.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding decisions on 20 January 1999.

Co-Rapporteur:

B. Odlind